EUROFINS CDMO, YOUR EXTENSIVE SUPPORT FOR DRUG DEVELOPMENT

Eurofins CDMO (Contract Development & Manufacturing Organization) network of companies provides integrated, end-to-end solutions for preclinical & clinical outsourcing services of both Drug Substance / API and Drug Product for Biologics and Small Molecules.

North America

Eurofins CDMO Alphora Inc.

Europe

Eurofins CDMO in Europe

Asia

Eurofins Advinus Inc.

DISCOVER OUR CDMO EXPERTISE

Biologics expertise

Find tailored support for your biologics from development to clinic

Small molecules expertise

End-to-end drug development solutions from research and development to finished products.

Services in the spotlight

Discover our key services to unleash your drug potential

EUROFINS CDMO

Drug Development & Manufacturing for pharmaceutical & biotech companies.

Our goal is to build a sustainable partnership with our customers to support their drug development pathway.

More about your CDMO Expert

  • Part of Eurofins Group
  • We span the Globe
  • An expert team
  • Team's Flexibility
  • Part of Eurofins Group
  • We span the Globe
  • An expert team
  • Team's Flexibility

Resources

The Relevance of Polymorph Screening in the Pharmaceutical Industry

Current Strategies for Enhancing Bioavailability of Poorly Soluble Compounds: A Discussion on Commonly Used Technologies & Supporting Services

API Development Tool Box: Case Studies in Multivariate Process Analysis

Stability studies and extension of shelf-life: The 10 commandments for Investigational Medicinal Products in EU

High-Throughput screening fo discovery of novel solid forms

Bahareh Khalili, PhD, Manager, Solid State Research & Development, Eurofins CDMO Alphora Inc.

Drug Product Enhanced Capabilities

Michelle Gischewski, Scientific Advisor – Drug Product Operations, Eurofins CDMO Alphora Inc.

Eurofins CDMO helps solve the rising challenge of colon drug delivery for biologics

Jody Voorspoels, Chief Scientific Officer, Eurofins CDMO Europe

Why Biotechs should make enhancing Bioavailability a priority

Labiotech.eu

Addressing sustainability of ATMPs by innovative platform approaches

Finding the right path for Cell & Gene therapy analytics (and more)

E&L considerations for ATMPS: challenges and possible strategies

The benefits of combining formulation and purification activitites during process developement

Highway to Clinic – Formulation Strategies for Improved Bioavailability

Discover our services in 2 minutes

Voice of our experts - Episode 1

Voice of our experts - Episode 2

Voice of our experts - Episode 3

NEWS & EVENTS

Check our latest news and find our next events

Bioeurope Fall

-

Worl Vaccine Congress

-

Festival of Biologics

-

A3P

-

More news More events

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi at nibh rhoncus, tempor magna non, feugiat nisi.